Pharmacogenomics Market Size, Share, Trends, Growth Outlook

The Global Pharmacogenomics Market Size is estimated to register 6.2% growth over the forecast period from 2024 to 2030.

 

The market growth is driven by increasing regulatory support and the development of guidelines for pharmacogenomic testing is driving the adoption of these technologies in clinical practice. Regulatory agencies, such as the FDA in the United States and the EMA in Europe, are guiding the integration of pharmacogenomic information into drug labeling and clinical decision-making. This regulatory clarity is fostering confidence among healthcare providers and encouraging the incorporation of pharmacogenomic testing into standard care protocols. Leading Companies focusing on Expansion of Drug Development and Clinical Trials, Incorporation into Public Health Initiatives, and others to boost market shares in the industry.

 

Pharmacogenomics Market Overview

The Pharmacogenomics Market, driven by advancements in genomic technologies and the demand for personalized medicine, integrates pharmacology and genomics to tailor medication therapy based on an individual's genetic makeup. Key players include pharmaceutical companies, diagnostic laboratories, and startups, leveraging technologies like NGS and microarray analysis. Clinical applications span various specialties, optimizing drug selection and dosing to enhance therapeutic outcomes while minimizing adverse reactions. Regulatory agencies like the FDA and EMA provide guidance, but challenges remain, including standardization and reimbursement. However, ongoing research and collaboration are driving growth, positioning pharmacogenomics as an integral component of future healthcare.

 

Pharmacogenomics Market Dynamics

Pharmacogenomics Market Trends- Pharmacogenomics unlocks personalized medicine, empowering smarter treatment decisions for a new era of healthcare.

Pharmacogenomics, which examines how an individual's genetic composition impacts their response to medications, is unlocking the potential of personalized medicine, marking a significant advancement in healthcare. Through the analysis of genetic variances, healthcare providers can customize treatment strategies based on each patient's specific genetic profile, resulting in more accurate and efficient medication management. This approach facilitates informed treatment decisions, pinpointing drugs likely to be effective while minimizing the risk of adverse reactions. By embracing pharmacogenomics, healthcare professionals can depart from the conventional one-size-fits-all prescribing model, transitioning towards a more individualized and precise approach to medication therapy. Ultimately, this shift holds promise for enhancing patient outcomes and transforming the delivery of healthcare services.

Market Driver- As genomic technologies unlock deeper insights into individual DNA, the demand for pharmacogenomics, which tailor’s medications to a patient's genetic makeup, is skyrocketing.

As genomic technologies uncover more about individual DNA, the demand for pharmacogenomics is surging. Pharmacogenomics, which customizes medications to match a patient's genetic profile, is increasingly vital in healthcare. This approach empowers healthcare providers to tailor treatment plans according to genetic differences, thereby enhancing drug effectiveness and minimizing adverse effects. With advancements in next-generation sequencing and bioinformatics, pharmacogenomics stands poised to transform medication management, especially in complex conditions like cancer, cardiovascular diseases, and psychiatric disorders. As awareness increases and regulatory frameworks adapt to accommodate genomic data, pharmacogenomics is anticipated to have a pivotal role in shaping the future of precision medicine.

Market Opportunity- The widespread adoption of Electronic Health Records (EHRs) is creating a surge in the pharmacogenomics market, as access to rich patient data facilitates personalized medicine approaches.

The rising prevalence of Electronic Health Records (EHRs) within healthcare systems worldwide is driving an increase in their integration with pharmacogenomics, consequently spurring growth in the market. EHRs serve as comprehensive repositories of patient information, encompassing medical history, laboratory findings, and medication records, all of which are indispensable for pharmacogenomic analysis. This trove of data empowers healthcare providers to pinpoint genetic variations influencing drug response and tailor treatment regimens accordingly. By leveraging EHRs to embed pharmacogenomic insights into clinical workflows, medical professionals can fine-tune medication selection, dosing, and monitoring on a personalized level, resulting in enhanced therapeutic efficacy and minimized adverse drug reactions. Moreover, the seamless fusion of pharmacogenomic data into EHR systems streamlines decision-making processes, boosting efficiency and precision, thereby propelling the advancement of personalized medicine strategies and fostering the ongoing expansion of the pharmacogenomics market.

Market Share Analysis- Kits and Reagents Pharmacogenomics Market will register the fastest growth

The Global Pharmacogenomics Market is analyzed across Kits and reagents, Services, and others. Kits & Reagents is poised to register the fastest growth. The Kits and Reagents segment in the Pharmacogenomics Market encompasses essential products for genetic testing and analysis, facilitating DNA or RNA extraction, amplification, and detection. These products include specialized reagents like PCR reagents, sequencing kits, and microarray probes, crucial for efficient and accurate pharmacogenomic testing in clinical and research settings. As the demand for personalized medicine grows, driven by advancements in genomic technologies and understanding of genetic influences on drug response, this segment is experiencing robust growth. Market players are innovating to develop advanced products with improved sensitivity and ease of use, while collaborations between pharmaceutical companies and diagnostic manufacturers are driving integrated solutions, further accelerating market expansion.

Market Share Analysis- Sequencing held a significant market share in 2024

The Global Pharmacogenomics Market is analyzed across various technologies including Sequencing, PCR, Microarray, and others. Of these, Sequencing held a significant market share in 2024. The Sequencing Pharmacogenomics Market utilizes advanced sequencing technologies like next-generation sequencing (NGS) to analyze genetic variations affecting drug response. By sequencing specific genes or the entire genome, healthcare providers can identify actionable genetic variants for personalized medication therapy, enhancing treatment efficacy and minimizing adverse reactions. Key drivers include technological advancements, increasing demand for precision medicine, and growing awareness of pharmacogenomic testing benefits. Major players include pharmaceutical companies, diagnostic labs, research institutions, and sequencing technology providers, all contributing to the integration of sequencing technologies into routine clinical care for improved patient outcomes.

 

Pharmacogenomics Market Segmentation

By Product & Service

• Kits & Reagents

• Sequencing Kits and Reagents
• PCR Kits and Reagents
• Microarray Kits and Reagents
• Others

• Service

 

By Technology

• Sequencing
• PCR
• Microarray
• Others

 

By Disease Area

• Cancer
• Cardiovascular
• Neurological Diseases
• Others

 

By Application

• Personalized Medicine
• Clinical Research
• Drug discovery and Preclinical Development

 

By End User

• Academic and Research Institutes
• Pharmaceutical and Biotechnology Companies
• Contract Research Organizations

 

By Region

• North America (United States, Canada, Mexico)
• Europe (Germany, France, United Kingdom, Spain, Italy, Others)
• Asia Pacific (China, India, Japan, South Korea, Australia, Others)
• Latin America (Brazil, Argentina, Others)
• Middle East and Africa (Saudi Arabia, UAE, Kuwait, Other Middle East, South Africa, Nigeria, Other Africa)

 

Pharmacogenomics Market Companies

• Illumina Inc (United States)
• Thermo Fisher Scientific Inc (United States)
• Danaher Corporation (United States)
• Laboratory Corporation of America Holdings (United States)
• Charles River Laboratories (United States)
• Eurofins Scientific (Luxembourg)
• Bio-Rad Laboratories Inc (United States)
• Agilent Technologies Inc (United States)
• BD (United States)
• QIAGEN (Netherlands)
• F Hoffmann-La Roche Ltd (Switzerland)
• Revvity (United States)
• IQVIA Inc. (United States)
• Mesa Labs Inc (United States)
• Medpace (United States)
• MGI Tech Co Ltd(China)
• Takara Bio Inc (Japan)
• PacBio (United States )
• New England Biolabs (United States)
• BGI (China)
• Novogene Co Ltd (China)
• SOPHiA GENETICS (Switzerland)
• Fios Genomics (United Kingdom)
• Personalis, Inc (United States)
• BioAI Health Inc (United States)
• NeoGenomics Laboratories (United States)
• Macrogen, Inc (South Korea)

 

*List not exhaustive

Pharmacogenomics Market Outlook 2024

1 Market Overview

1.1 Introduction to the Pharmacogenomics Market

1.2 Scope of the Study

1.3 Research Objective

1.3.1 Key Market Scope and Segments

1.3.2 Players Covered

1.3.3 Years Considered

 

2 Executive Summary

2.1 2024 Pharmacogenomics Industry- Market Statistics

3 Market Dynamics

3.1 Market Drivers

3.2 Market Challenges

3.3 Market Opportunities

3.4 Market Trends

 

4 Market Factor Analysis

4.1 Porter’s Five Forces

4.2 Market Entropy

4.2.1 Global Pharmacogenomics Market Companies with Area Served

4.2.2 Products Offerings Global Pharmacogenomics Market

 

5 Recession Impact Analysis and Outlook Scenarios

5.1.1 Recission Impact Analysis

5.1.2 Market Growth Scenario- Base Case

5.1.3 Market Growth Scenario- Reference Case

5.1.4 Market Growth Scenario- High Case

 

6 Global Pharmacogenomics Market Trends

6.1 Global Pharmacogenomics Revenue (USD Million) and CAGR (%) by Type (2018-2032)

6.2 Global Pharmacogenomics Revenue (USD Million) and CAGR (%) by Applications (2018-2032)

6.3 Global Pharmacogenomics Revenue (USD Million) and CAGR (%) by regions (2018-2032)

 

7 Global Pharmacogenomics Market Revenue (USD Million) by Type, and Applications (2018-2023)

7.1 Global Pharmacogenomics Revenue (USD Million) by Type (2018-2023)

7.1.1 Global Pharmacogenomics Revenue (USD Million), Market Share (%) by Type (2018-2023)

7.2 Global Pharmacogenomics Revenue (USD Million) by Applications (2018-2023)

7.2.1 Global Pharmacogenomics Revenue (USD Million), Market Share (%) by Applications (2018-2023)

 

8 Global Pharmacogenomics Development Regional Status and Outlook

8.1 Global Pharmacogenomics Revenue (USD Million) By Regions (2018-2023)

8.2 North America Pharmacogenomics Revenue (USD Million) by Type, and Application (2018-2023)

8.2.1 North America Pharmacogenomics Revenue (USD Million) by Country (2018-2023)

8.2.2 North America Pharmacogenomics Revenue (USD Million) by Type (2018-2023)

8.2.3 North America Pharmacogenomics Revenue (USD Million) by Applications (2018-2023)

8.3 Europe Pharmacogenomics Revenue (USD Million), by Type, and Applications (USD Million) (2018-2023)

8.3.1 Europe Pharmacogenomics Revenue (USD Million), by Country (2018-2023)

8.3.2 Europe Pharmacogenomics Revenue (USD Million) by Type (2018-2023)

8.3.3 Europe Pharmacogenomics Revenue (USD Million) by Applications (2018-2023)

8.4 Asia Pacific Pharmacogenomics Revenue (USD Million), and Revenue (USD Million) by Type, and Applications (2018-2023)

8.4.1 Asia Pacific Pharmacogenomics Revenue (USD Million) by Country (2018-2023)

8.4.2 Asia Pacific Pharmacogenomics Revenue (USD Million) by Type (2018-2023)

8.4.3 Asia Pacific Pharmacogenomics Revenue (USD Million) by Applications (2018-2023)

8.5 South America Pharmacogenomics Revenue (USD Million), by Type, and Applications (2018-2023)

8.5.1 South America Pharmacogenomics Revenue (USD Million), by Country (2018-2023)

8.5.2 South America Pharmacogenomics Revenue (USD Million) by Type (2018-2023)

8.5.3 South America Pharmacogenomics Revenue (USD Million) by Applications (2018-2023)

8.6 Middle East and Africa Pharmacogenomics Revenue (USD Million), by Type, Technology, Application, Thickness (2018-2023)

8.6.1 Middle East and Africa Pharmacogenomics Revenue (USD Million) by Country (2018-2023)

8.6.2 Middle East and Africa Pharmacogenomics Revenue (USD Million) by Type (2018-2023)

8.6.3 Middle East and Africa Pharmacogenomics Revenue (USD Million) by Applications (2018-2023)

 

9 Company Profiles

 

10 Global Pharmacogenomics Market Revenue (USD Million), by Type, and Applications (2024-2032)

10.1 Global Pharmacogenomics Revenue (USD Million) and Market Share (%) by Type (2024-2032)

10.1.1 Global Pharmacogenomics Revenue (USD Million), and Market Share (%) by Type (2024-2032)

10.2 Global Pharmacogenomics Revenue (USD Million) and Market Share (%) by Applications (2024-2032)

10.2.1 Global Pharmacogenomics Revenue (USD Million), and Market Share (%) by Applications (2024-2032)

 

11 Global Pharmacogenomics Development Regional Status and Outlook Forecast

11.1 Global Pharmacogenomics Revenue (USD Million) By Regions (2024-2032)

11.2 North America Pharmacogenomics Revenue (USD Million) by Type, and Applications (2024-2032)

11.2.1 North America Pharmacogenomics Revenue (USD) Million by Country (2024-2032)

11.2.2 North America Pharmacogenomics Revenue (USD Million), by Type (2024-2032)

11.2.3 North America Pharmacogenomics Revenue (USD Million), Market Share (%) by Applications (2024-2032)

11.3 Europe Pharmacogenomics Revenue (USD Million), by Type, and Applications (2024-2032)

11.3.1 Europe Pharmacogenomics Revenue (USD Million), by Country (2024-2032)

11.3.2 Europe Pharmacogenomics Revenue (USD Million), by Type (2024-2032)

11.3.3 Europe Pharmacogenomics Revenue (USD Million), by Applications (2024-2032)

11.4 Asia Pacific Pharmacogenomics Revenue (USD Million) by Type, and Applications (2024-2032)

11.4.1 Asia Pacific Pharmacogenomics Revenue (USD Million), by Country (2024-2032)

11.4.2 Asia Pacific Pharmacogenomics Revenue (USD Million), by Type (2024-2032)

11.4.3 Asia Pacific Pharmacogenomics Revenue (USD Million), by Applications (2024-2032)

11.5 South America Pharmacogenomics Revenue (USD Million), by Type, and Applications (2024-2032)

11.5.1 South America Pharmacogenomics Revenue (USD Million), by Country (2024-2032)

11.5.2 South America Pharmacogenomics Revenue (USD Million), by Type (2024-2032)

11.5.3 South America Pharmacogenomics Revenue (USD Million), by Applications (2024-2032)

11.6 Middle East and Africa Pharmacogenomics Revenue (USD Million), by Type, and Applications (2024-2032)

11.6.1 Middle East and Africa Pharmacogenomics Revenue (USD Million), by region (2024-2032)

11.6.2 Middle East and Africa Pharmacogenomics Revenue (USD Million), by Type (2024-2032)

11.6.3 Middle East and Africa Pharmacogenomics Revenue (USD Million), by Applications (2024-2032)

 

12 Methodology and Data Sources

12.1 Methodology/Research Approach

12.1.1 Research Programs/Design

12.1.2 Market Size Estimation

12.1.3 Market Breakdown and Data Triangulation

12.2 Data Sources

12.2.1 Secondary Sources

12.2.2 Primary Sources

12.3 Disclaimer

 

List of Tables

Table 1 Market Segmentation Analysis

Table 2 Global Pharmacogenomics Market Companies with Areas Served

Table 3 Products Offerings Global Pharmacogenomics Market

Table 4 Low Growth Scenario Forecasts

Table 5 Reference Case Growth Scenario

Table 6 High Growth Case Scenario

Table 7 Global Pharmacogenomics Revenue (USD Million) And CAGR (%) By Type (2018-2032)

Table 8 Global Pharmacogenomics Revenue (USD Million) And CAGR (%) By Applications (2018-2032)

Table 9 Global Pharmacogenomics Revenue (USD Million) And CAGR (%) By Regions (2018-2032)

Table 10 Global Pharmacogenomics Revenue (USD Million) By Type (2018-2023)

Table 11 Global Pharmacogenomics Revenue Market Share (%) By Type (2018-2023)

Table 12 Global Pharmacogenomics Revenue (USD Million) By Applications (2018-2023)

Table 13 Global Pharmacogenomics Revenue Market Share (%) By Applications (2018-2023)

Table 14 Global Pharmacogenomics Market Revenue (USD Million) By Regions (2018-2023)

Table 15 Global Pharmacogenomics Market Share (%) By Regions (2018-2023)

Table 16 North America Pharmacogenomics Revenue (USD Million) By Country (2018-2023)

Table 17 North America Pharmacogenomics Revenue (USD Million) By Type (2018-2023)

Table 18 North America Pharmacogenomics Revenue (USD Million) By Applications (2018-2023)

Table 19 Europe Pharmacogenomics Revenue (USD Million) By Country (2018-2023)

Table 20 Europe Pharmacogenomics Revenue (USD Million) By Type (2018-2023)

Table 21 Europe Pharmacogenomics Revenue (USD Million) By Applications (2018-2023)

Table 22 Asia Pacific Pharmacogenomics Revenue (USD Million) By Country (2018-2023)

Table 23 Asia Pacific Pharmacogenomics Revenue (USD Million) By Type (2018-2023)

Table 24 Asia Pacific Pharmacogenomics Revenue (USD Million) By Applications (2018-2023)

Table 25 South America Pharmacogenomics Revenue (USD Million) By Country (2018-2023)

Table 26 South America Pharmacogenomics Revenue (USD Million) By Type (2018-2023)

Table 27 South America Pharmacogenomics Revenue (USD Million) By Applications (2018-2023)

Table 28 Middle East and Africa Pharmacogenomics Revenue (USD Million) By Region (2018-2023)

Table 29 Middle East and Africa Pharmacogenomics Revenue (USD Million) By Type (2018-2023)

Table 30 Middle East and Africa Pharmacogenomics Revenue (USD Million) By Applications (2018-2023)

Table 31 Financial Analysis

Table 32 Global Pharmacogenomics Revenue (USD Million) By Type (2024-2032)

Table 33 Global Pharmacogenomics Revenue Market Share (%) By Type (2024-2032)

Table 34 Global Pharmacogenomics Revenue (USD Million) By Applications (2024-2032)

Table 35 Global Pharmacogenomics Revenue Market Share (%) By Applications (2024-2032)

Table 36 Global Pharmacogenomics Market Revenue (USD Million), And Revenue (USD Million) By Regions (2024-2032)

Table 37 North America Pharmacogenomics Revenue (USD)By Country (2024-2032)

Table 38 North America Pharmacogenomics Revenue (USD Million) By Type (2024-2032)

Table 39 North America Pharmacogenomics Revenue (USD Million) By Applications (2024-2032)

Table 40 Europe Pharmacogenomics Revenue (USD Million) By Country (2024-2032)

Table 41 Europe Pharmacogenomics Revenue (USD Million) By Type (2024-2032)

Table 42 Europe Pharmacogenomics Revenue (USD Million) By Applications (2024-2032)

Table 43 Asia Pacific Pharmacogenomics Revenue (USD Million) By Country (2024-2032)

Table 44 Asia Pacific Pharmacogenomics Revenue (USD Million) By Type (2024-2032)

Table 45 Asia Pacific Pharmacogenomics Revenue (USD Million) By Applications (2024-2032)

Table 46 South America Pharmacogenomics Revenue (USD Million) By Country (2024-2032)

Table 47 South America Pharmacogenomics Revenue (USD Million) By Type (2024-2032)

Table 48 South America Pharmacogenomics Revenue (USD Million) By Applications (2024-2032)

Table 49 Middle East and Africa Pharmacogenomics Revenue (USD Million) By Region (2024-2032)

Table 50 Middle East and Africa Pharmacogenomics Revenue (USD Million) By Region (2024-2032)

Table 51 Middle East and Africa Pharmacogenomics Revenue (USD Million) By Type (2024-2032)

Table 52 Middle East and Africa Pharmacogenomics Revenue (USD Million) By Applications (2024-2032)

Table 53 Research Programs/Design for This Report

Table 54 Key Data Information from Secondary Sources

Table 55 Key Data Information from Primary Sources

 

List of Figures

Figure 1 Market Scope

Figure 2 Porter’s Five Forces

Figure 3 Global Pharmacogenomics Revenue (USD Million) By Type (2018-2023)

Figure 4 Global Pharmacogenomics Revenue Market Share (%) By Type (2023)

Figure 5 Global Pharmacogenomics Revenue (USD Million) By Applications (2018-2023)

Figure 6 Global Pharmacogenomics Revenue Market Share (%) By Applications (2023)

Figure 7 Global Pharmacogenomics Market Revenue (USD Million) By Regions (2018-2023)

Figure 8 Global Pharmacogenomics Market Share (%) By Regions (2023)

Figure 9 North America Pharmacogenomics Revenue (USD Million) By Country (2018-2023)

Figure 10 North America Pharmacogenomics Revenue (USD Million) By Type (2018-2023)

Figure 11 North America Pharmacogenomics Revenue (USD Million) By Applications (2018-2023)

Figure 12 Europe Pharmacogenomics Revenue (USD Million) By Country (2018-2023)

Figure 13 Europe Pharmacogenomics Revenue (USD Million) By Type (2018-2023)

Figure 14 Europe Pharmacogenomics Revenue (USD Million) By Applications (2018-2023)

Figure 15 Asia Pacific Pharmacogenomics Revenue (USD Million) By Country (2018-2023)

Figure 16 Asia Pacific Pharmacogenomics Revenue (USD Million) By Type (2018-2023)

Figure 17 Asia Pacific Pharmacogenomics Revenue (USD Million) By Applications (2018-2023)

Figure 18 South America Pharmacogenomics Revenue (USD Million) By Country (2018-2023)

Figure 19 South America Pharmacogenomics Revenue (USD Million) By Type (2018-2023)

Figure 20 South America Pharmacogenomics Revenue (USD Million) By Applications (2018-2023)

Figure 21 Middle East and Africa Pharmacogenomics Revenue (USD Million) By Region (2018-2023)

Figure 22 Middle East and Africa Pharmacogenomics Revenue (USD Million) By Type (2018-2023)

Figure 23 Middle East and Africa Pharmacogenomics Revenue (USD Million) By Applications (2018-2023)

Figure 24 Global Pharmacogenomics Revenue (USD Million) By Type (2024-2032)

Figure 25 Global Pharmacogenomics Revenue Market Share (%) By Type (2030)

Figure 26 Global Pharmacogenomics Revenue (USD Million) By Applications (2024-2032)

Figure 27 Global Pharmacogenomics Revenue Market Share (%) By Applications (2030)

Figure 28 Global Pharmacogenomics Market Revenue (USD Million) By Regions (2024-2032)

Figure 29 North America Pharmacogenomics Revenue (USD Million) By Country (2024-2032)

Figure 30 North America Pharmacogenomics Revenue (USD Million) By Type (2024-2032)

Figure 31 North America Pharmacogenomics Revenue (USD Million) By Applications (2024-2032)

Figure 32 Europe Pharmacogenomics Revenue (USD Million) By Country (2024-2032)

Figure 33 Europe Pharmacogenomics Revenue (USD Million) By Type (2024-2032)

Figure 34 Europe Pharmacogenomics Revenue (USD Million) By Applications (2024-2032)

Figure 35 Asia Pacific Pharmacogenomics Revenue (USD Million) By Country (2024-2032)

Figure 36 Asia Pacific Pharmacogenomics Revenue (USD Million) By Type (2024-2032)

Figure 37 Asia Pacific Pharmacogenomics Revenue (USD Million) By Applications (2024-2032)

Figure 38 South America Pharmacogenomics Revenue (USD Million) By Country (2024-2032)

Figure 39 South America Pharmacogenomics Revenue (USD Million) By Type (2024-2032)

Figure 40 South America Pharmacogenomics Revenue (USD Million) By Applications (2024-2032)

Figure 41 Middle East and Africa Pharmacogenomics Revenue (USD Million) By Region (2024-2032)

Figure 42 Middle East and Africa Pharmacogenomics Revenue (USD Million) By Region (2024-2032)

Figure 43 Middle East and Africa Pharmacogenomics Revenue (USD Million) By Type (2024-2032)

Figure 44 Middle East and Africa Pharmacogenomics Revenue (USD Million) By Applications (2024-2032)

Figure 45 Bottom-Up and Top-Down Approaches for This Report

Figure 46 Data Triangulation

Pharmacogenomics Market Segmentation

By Product & Service

• Kits & Reagents

• Sequencing Kits and Reagents
• PCR Kits and Reagents
• Microarray Kits and Reagents
• Others

• Service

 

By Technology

• Sequencing
• PCR
• Microarray
• Others

 

By Disease Area

• Cancer
• Cardiovascular
• Neurological Diseases
• Others

 

By Application

• Personalized Medicine
• Clinical Research
• Drug discovery and Preclinical Development

 

By End User

• Academic and Research Institutes
• Pharmaceutical and Biotechnology Companies
• Contract Research Organizations

 

By Region

• North America (United States, Canada, Mexico)
• Europe (Germany, France, United Kingdom, Spain, Italy, Others)
• Asia Pacific (China, India, Japan, South Korea, Australia, Others)
• Latin America (Brazil, Argentina, Others)
• Middle East and Africa (Saudi Arabia, UAE, Kuwait, Other Middle East, South Africa, Nigeria, Other Africa)